The Leona M. and Harry B. Helmsley Charitable Trust
The Leona M. and Harry B. Helmsley Charitable Trust is an independent non-profit private foundation based in New York City, established in 1999. Its mission is to enhance lives by providing support to exceptional nonprofits and mission-aligned organizations both in the United States and internationally. The foundation focuses on key areas including health, education, and human services, with specific program initiatives targeting conservation, inflammatory bowel disease and Crohn's disease, rural healthcare, type 1 diabetes, and vulnerable children in Sub-Saharan Africa. The foundation's assets are managed by an executive management team dedicated to fulfilling its philanthropic goals.
Thetis Pharmaceuticals
Debt Financing in 2025
Thetis Pharmaceuticals LLC is a biopharmaceutical company based in Branford, Connecticut, founded in 2011. The company specializes in developing immuno-resolving therapeutic solutions aimed at treating inflammatory bowel diseases and other inflammatory conditions. Utilizing its HEALER technology platform, Thetis Pharmaceuticals focuses on the pharmacology of lipids to create new and patented small molecule drugs that promote tissue regeneration and mitigate inflammation. Their research has advanced the development of resolvins, which act as potent agonists of inflammation resolution and tissue repair. These therapies are designed to counteract excessive inflammatory responses while preserving immune function, thereby enabling healthcare professionals to better manage patients' inflammatory conditions.
Thetis Pharmaceuticals
Grant in 2022
Thetis Pharmaceuticals LLC is a biopharmaceutical company based in Branford, Connecticut, founded in 2011. The company specializes in developing immuno-resolving therapeutic solutions aimed at treating inflammatory bowel diseases and other inflammatory conditions. Utilizing its HEALER technology platform, Thetis Pharmaceuticals focuses on the pharmacology of lipids to create new and patented small molecule drugs that promote tissue regeneration and mitigate inflammation. Their research has advanced the development of resolvins, which act as potent agonists of inflammation resolution and tissue repair. These therapies are designed to counteract excessive inflammatory responses while preserving immune function, thereby enabling healthcare professionals to better manage patients' inflammatory conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.